Pocket Novel Download
Evie Dobbe
Really helpful information, Jenny. The pay for a pocket novel doesn't seem much compared to a short story so its really good to know what else you can expect/hope to get from your manuscript and all the links and details are especially helpful.
Thanks, Patsy too, for posting.
Alyson
Thanks to all for their appreciative comments and of course MASSIVE thanks to Patsy for this and for all the other brilliantly helpful advice on her Womag Blog. It really is an invaluable resource.
John - glad it helped you with PLR.
Alyson - yes, the pay doesn't really make sense when compared per word with a short story, so it's good PNs have an 'after-life'. I do think also that PNs are quicker to write per page, if you see what I mean. Once you start writing a novella, the words flow and it doesn't seem to need the same sort of forensic re-examination that a short story demands. It can take an awfully long time to write a short story! (or maybe it's just me...?).
Carrie - good luck with your PN!
Tracey - can't wait to tour the libraries! My first self-published novel is already in our local library but ONLY because I donated a copy. They said they used to have money to buy novels by local authors but due to cuts...you know the rest.
Liz - a very kind comment. Thank you.
Thanks again to Patsy who selflessly gives up so much time to this blog. It was only when I was trying to put something together last Saturday for the article that I fully appreciated how extremely time consuming it is. Patsy - we all owe you a lot! And we're really grateful.
Everyone Pampers the Small Blessing Who Has a Spatial Pocket! novel is a popular light novel covering Romance, Psychological genres. Written by the Author Undamaged Bamboo . Read Everyone Pampers the Small Blessing Who Has a Spatial Pocket! novel online for free.
Citation: Abdelnabi R, Geraets JA, Ma Y, Mirabelli C, Flatt JW, Domanska A, et al. (2019) A novel druggable interprotomer pocket in the capsid of rhino- and enteroviruses. PLoS Biol 17(6): e3000281.
(A) The atomic model of CVB3 Nancy in complex with compound 17 based on the cryo-EM density shows the position of the drug at an interprotomer site, located between adjacent VP1 chains (gray and blue) and VP3 (red). (B) Difference density for compound 17 (mesh), with an atomic model of compound 17 fitted in, shown at 1.5 standard deviations above the mean. (C) The process of difference mapping: simulated density map was generated from 1COV for the capsid proteins (here colored blue, light blue, red by protein) and normalized to the cryo-EM density map in UCSF Chimera. When the simulated density map of 1COV was then subtracted from the cryo-EM density, the difference density remained (orange). (D) Model docked into map. (E) Electrostatic analysis of the surface pocket. The raw cryoelectron microscopy data are deposited in the EMPIAR (Electron Microscopy Public Image Archive) database with the ID: EMPIAR-10199. CVB, Coxsackievirus B; EM, electron microscopy; UCSF, University California San Francisco.
A clonal in vitro resistance selection [13] was performed to select compound-resistant virus variants. Four resistance mutations were identified mapping to the VP1 coding region of the genome. Three of the four amino acid mutations were located in the pocket vicinity: F76C, E78G, and A98V, and one in the 5-fold vertex region (D133G) (Fig 2D, S4A Fig). Twelve reverse-engineered CVB3 mutants were generated in a CVB3 infectious clone (Nancy strain). These were selected based on (i) residues that line the pocket in the atomic model and (ii) mutations identified in the resistance selection to compound 17. In addition, the glutathione-independent VP1_T77M CVB3 variant was engineered (that is resistant to the glutathione-depleting compound TP0219) [15]. Of these mutants, eight proved viable (Table 1 and Fig 2D) and were further investigated, whereas four were not viable (VP1_Q160G and VP1_R234G, VP3_F236G and VP3_Q233G). Seven out of the eight variants proved resistant to compound 17 and were equally sensitive to the control compound, i.e., the 3C protease inhibitor rupintrivir (Table 1). These results validate the importance of the pocket residues for compound 17 activity.
As for the only resistance mutation located outside the interprotomer pocket, the thermostability profile of the VP1_D133G variant revealed that it is more heat sensitive than the CVB3 Nancy (the mutation destabilizes the viral capsid) and that compound 17 could still stabilize the variant (S4B Fig). Hence, VP1_D133G is a compensatory mutation rather than a mutation that prevents compound 17 binding. The growth kinetics and plaque phenotyping of the variant revealed that the mutation slightly decreases virus fitness (S4C Fig).
Pockets traditionally make more attractive targets for drug design and optimization than flat surfaces, as they can accommodate larger surface areas and hence contribute more residues for interaction. For the same reason, pockets such as the hydrophobic site found within VP1 of most enteroviruses play important functional roles during virus entry and replication. Until now, the hydrophobic canyon site has been the only explored surface pocket for enteroviruses. The cryo-EM structure of CVB3 in complex with compound 17 revealed that 16 residues line the interprotomer pocket and provided a plausible explanation for most of the observed resistance mutations identified by selection. To confirm the druggable site, several of the residues were mutated, and the resulting viruses had indeed reduced sensitivity to compound 17. There were several amino acid residues in the pocket that could not be mutated, highlighting the importance of this pocket in the biology of enterovirus replication. Residues in the pocket allow quaternary structural changes in the capsid as it progresses from the virion to an expanded altered particle (A-particle) during entry, primed for RNA release [2,18], a process common to many picornaviruses [2]. This expansion requires rotation and translation of VP1, relative to itself, and to VP3 and VP2, a process dependent on movements along the interprotomer interfaces, including the region containing the pocket described here. Comparison of several structures of expanded picornavirus particles revealed that in the expanded particle, the pocket has an altered shape caused by the movement of the VP3 C terminus; this includes the residues that line the pocket (Q233, Q234, N235, F236). Hence, we propose that binding of compounds in this pocket stabilizes the conformation of a key region of the virion, preventing rearrangements that allow transition to the A-particle. The resistant mutant distant to the pocket (VP1-D133G) destabilizes the particle sufficiently so that the energy barrier to the transition is lowered, compensating for the increased stability induced by the drug, and thus still allowing release of the RNA.
To conclude, compound 17 and its analogues are selective inhibitors of CVB3 replication that target a novel pocket on the surface of the capsid that is important in conformational changes required for RNA release from the viral particle. Cryo-EM structural data and in vitro resistance selection together with reverse engineering revealed a set of amino acid residues in the virion that are crucial for the compound activity and allowed us to propose a unique mechanism of antiviral action. Antiviral evaluation of a set of compound 17 analogues indicates that it is possible to target EV-B, EV-C, EV-D, and even rhinovirus (A and B) species. In addition, computational analysis suggests that the pocket is partially conserved across species, including the RV-C species that are naturally resistant to pleconaril (and molecules with a similar mechanism of action) and EV-A. However, the shape and electrostatic properties of the pocket are sufficiently different in those latter species so that further study is required to design molecules that also block viruses belonging to these species (S3 and S4 Tables). Medicinal chemistry efforts are ongoing to replace the carboxylic acid moiety in the core structure of this class of compounds with more stable moieties, such as (bio)isosteres. Hence, we foresee the development of a future series of analogues with improved activity and spectrum against an important group of viruses that cause significant infectious illnesses worldwide.
No, my only self-imposed stipulation is that they are all set in the 20th century. I have a particular, personal preference for the late 40s and early 50s but I have also chosen the 60s, 90s and the present day as the setting for my novels.
In order to support bioinformatics predictions and to identify the ligand binding pocket of GPCRs, random mutagenesis and subsequent activity assays are performed. In addition, molecular-physical approaches, such as Atomic Force Microscopy (AFM), enable quantitative analysis of the binding concept. However, working with purified GPCR molecules is not feasible because their dynamic properties may change when isolated from the lipid bilayer. Intermediate solutions such as integrating them into liposomes may provide a solution10,11. Yet, in order to understand their proper physiological responses GPCRs should be examined directly on the cell surface. Single molecule force spectroscopy via AFM has been used successfully on living cells to measure the strength of ligand binding of transporter proteins12 and integrins13 while the same studies on GPCRs are limited14.
This study presents a combined computational, molecular and nano-scale approach. A novel type C AlstR was identified from the Indian stick insect, Carausius morosus. The combination of bioinformatics, site directed mutagenesis and single molecule force spectroscopy (SMFS) allowed us to reveal its binding pocket. The methodology used in this study may provide an applicable method for further studies on the binding pocket of GPCRs, that would allow for the design of agonist/inverse agonists.
f448fe82f3